Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED-Initiated Oral Naltrexone for AUD
NCT04817410Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone in alcohol use disorder (AUD), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Number of Participants Enrolled and Receiving Formal Addiction Treatment at 30 days. Started Sep 2021; status: completed.
02
Drugs
naltrexone
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT04817410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817410.